Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?
Autore:
Bantick, RA; Deakin, JFW; Grasby, PM;
Indirizzi:
Hammersmith Hosp, MRC, Cyclotron Unit, London W12 0NN, England HammersmithHosp London England W12 0NN on Unit, London W12 0NN, England Univ Manchester, Neurosci & Psychiat Unit, Manchester, Lancs, England UnivManchester Manchester Lancs England nit, Manchester, Lancs, England
Titolo Testata:
JOURNAL OF PSYCHOPHARMACOLOGY
fascicolo: 1, volume: 15, anno: 2001,
pagine: 37 - 46
SICI:
0269-8811(2001)15:1<37:T5RISA>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
HALOPERIDOL-INDUCED CATALEPSY; MEDIAL PREFRONTAL CORTEX; INDUCED DOPAMINE RELEASE; FREELY-MOVING RATS; (5-HT)(1A) AGONIST PROPERTIES; PLACEBO-CONTROLLED TRIAL; VENTRAL TEGMENTAL AREA; LONG-TERM TREATMENT; NUCLEUS-ACCUMBENS; HUMAN-BRAIN;
Keywords:
atypical antipsychotic; dopamine; glutamate; B-HT1A receptor; review; schizophrenia;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
109
Recensione:
Indirizzi per estratti:
Indirizzo: Bantick, RA Hammersmith Hosp, MRC, Cyclotron Unit, Du Cane Rd, London W12 0NN, England Hammersmith Hosp Du Cane Rd London England W12 0NN N, England
Citazione:
R.A. Bantick et al., "The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?", J PSYCHOPH, 15(1), 2001, pp. 37-46

Abstract

Increasing attention is being directed towards the role of the serotonergic system in the neurochemistry of schizophrenia and antipsychotic drug treatment. This review considers the 5-HT1A receptor in this context. In patients with schizophrenia, the majority of post-mortem studies have reported increases in 5-HT1A receptor density in the prefrontal cortex in the approximate range 15-80%. Although the pathophysiological significance of this finding is unclear, given the location of a major proportion of these receptorson pyramidal cells, it may reflect an abnormal glutamatergic network. In terms of drug treatment, 5-HT1A agonists clearly display anticataleptic activity in rats. In addition, 5-HT1A agonists consistently increase dopamine release in the prefrontal cortex in rodents, which is an effect that might be predicted to improve negative symptoms. 5-HT1A agonists augment classicalneuroleptics in some rat models of antipsychotic action and may be capableof modulating the glutamatergic network therapeutically. Despite the encouraging preclinical data, there is a paucity of clinical studies of 5-HT1A agonist augmentation of neuroleptics in the treatment of schizophrenia. However, the clinical relevance may be clarified by the atypical antipsychotic drugs clozapine, quetiapine and ziprasidone which combine D-2 receptor antagonism and 5-HT1A agonism. In conclusion, given the increased prefrontal 5-HT1A receptor density in the illness, and the anticataleptic activity of 5-HT1A agonists combined with their ability to evoke prefrontal dopamine release, there is now a sufficient rationale to examine thoroughly the role of the 5-HT1A receptor in schizophrenia and antipsychotic drug treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 19:35:19